tradingkey.logo

Fulgent Genetics Inc

FLGT
查看詳細走勢圖
26.720USD
-0.290-1.07%
收盤 12/26, 16:00美東報價延遲15分鐘
824.42M總市值
虧損本益比TTM

Fulgent Genetics Inc

26.720
-0.290-1.07%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-1.07%

5天

-3.22%

1月

-11.38%

6月

+35.77%

今年開始到現在

+44.67%

1年

+45.45%

查看詳細走勢圖

TradingKey Fulgent Genetics Inc股票評分

單位: USD 更新時間: 2025-12-26

操作建議

Fulgent Genetics Inc當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在醫療服務供應商行業排名39/78位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價33.67。中期看,股價處於上升通道。近一個月,市場表現較差,但基本面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Fulgent Genetics Inc評分

相關信息

行業排名
39 / 78
全市場排名
185 / 4563
所屬行業
醫療服務供應商

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 3 分析師
買入
評級
33.667
目標均價
+20.84%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Fulgent Genetics Inc亮點

亮點風險
Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.

Fulgent Genetics Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Fulgent Genetics Inc簡介

Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
公司代碼FLGT
公司Fulgent Genetics Inc
CEOHsieh (Ming)
網址https://www.fulgentgenetics.com/

常見問題

Fulgent Genetics Inc(FLGT)的當前股價是多少?

Fulgent Genetics Inc(FLGT)的當前股價是 26.720。

Fulgent Genetics Inc 的股票代碼是什麼?

Fulgent Genetics Inc的股票代碼是FLGT。

Fulgent Genetics Inc股票的52週最高點是多少?

Fulgent Genetics Inc股票的52週最高點是31.040。

Fulgent Genetics Inc股票的52週最低點是多少?

Fulgent Genetics Inc股票的52週最低點是14.570。

Fulgent Genetics Inc的市值是多少?

Fulgent Genetics Inc的市值是824.42M。

Fulgent Genetics Inc的淨利潤是多少?

Fulgent Genetics Inc的淨利潤為-42.71M。

現在Fulgent Genetics Inc(FLGT)的股票是買入、持有還是賣出?

根據分析師評級,Fulgent Genetics Inc(FLGT)的總體評級為買入,目標價格為33.667。

Fulgent Genetics Inc(FLGT)股票的每股收益(EPS TTM)是多少

Fulgent Genetics Inc(FLGT)股票的每股收益(EPS TTM)是-1.397。
KeyAI